Conclusion
The introduction of mAbs into the clinic has fundamentally changed cancer therapy. Nevertheless, it has increasingly become apparent that mAbs mediate their effects via a multitude of different mechanisms of action. Since the selection of the correct Ig isotype was recognised as crucial, much effort was put into understanding the Fc-mediated effects of different antibody isotypes as well as into Fc-modifications for further improvement of mAbs efficacy. Consequently, several strategies have been developed in order to optimise Fc-mediated effector functions, opening entirely novel opportunities to improve mAbs-based cancer therapy. Furthermore, by considering patient-related factors such as their immune status, characteristics of the TME or FcγR polymorphism, the isotype selection may either allow for the development of antibodies that are active in a wider range of patients or may allow for the selective use of antibodies tailored towards the individual’s needs. Such considerations may lead us one step further to patient-tailored medicine and more effective mAb treatment in the future.